Detection of actionable molecular alterations through combined DNA/RNA molecular profiling of biopsies collected in early-stage lung cancer at time of diagnosis.
Joshua Babiarz(Veracyte (United States)), Giulia C. Kennedy(Veracyte (United States)), David S. Wilson(Johns Hopkins University), Bailey Griscom(Veracyte (United States)), Yangyang Hao(Indiana University School of Medicine), William Krimsky(MedStar Franklin Square Medical Center), Hans C. Lee(The University of Texas MD Anderson Cancer Center), P. Sean Walsh(Veracyte (United States)), Christina Bellinger, Lori Lofaro(Veracyte (United States)), Saiyad Sarkar(MedStar Franklin Square Medical Center), Jing Huang(Veracyte (United States)), Alexander Chen(University of Nevada, Las Vegas), Jonathan I. Wilde(Veracyte (United States)), Manqiu Cao(Veracyte (United States)), Michael A. Bernstein(University of California, San Francisco), Momen M. Wahidi(Northwestern University), Sangeeta Bhorade(University of Chicago)
Cited by 1
Related Papers
Mammalian microRNAs: experimental evaluation of novel and previously annotated genes
|Genes & Development|2010|841
Clinical Risk Factors for Primary Graft Dysfunction after Lung Transplantation
|American Journal of Respiratory and Critical Care Medicine|2013|686
Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas
|Nature Medicine|2020|593
Management of Immunotherapy-Related Toxicities, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2019|560
Technical Aspects of Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration
|CHEST Journal|2015|445